Article
Surgery
Hordur Mar Kolbeinsson, Tyler Wall, Aqieda Bayat, Martin Luchtefeld, James W. Ogilvie
Summary: The study found that the risk of Crohn's disease and chronic pouchitis is higher in patients undergoing IPAA surgery for ulcerative colitis, significantly increasing the likelihood of pouch failure.
AMERICAN JOURNAL OF SURGERY
(2022)
Article
Gastroenterology & Hepatology
Sigrid Lindh, Jonas Bengtsson, Jerzy Kaczynski
Summary: This retrospective study evaluates the effectiveness of biologic therapy for antibiotic-refractory pouchitis. The majority of patients responded well or partially to biologic therapy, especially those who were naive to previous treatment. Second-line treatment should be considered for patients who do not respond to first-line treatment. Caution should be exercised when using Infliximab for non-naive patients due to the risk of adverse reactions.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Julian Hercun, Justin Cote-Daigneault, Raymond G. Lahaie, Carole Richard, Ramses Wassef, Pierre Poitras
Summary: The study found that Crohn's disease can develop postoperatively with an increasing cumulative incidence over time. Preoperative predictive factors are limited and should not determine candidacy for surgery. Most patients have favorable outcomes with medical therapy, while 16% of Crohn's disease patients require pouch removal.
DISEASES OF THE COLON & RECTUM
(2021)
Review
Gastroenterology & Hepatology
Amy L. Lightner, Xue Jia, Karen Zaghiyan, Phillip R. Fleshner
Summary: The study found that in patients with known preoperative Crohn's disease, the construction of ileal pouch anal anastomoses resulted in functional outcomes equivalent to patients with ulcerative colitis. However, even in highly selected patients with Crohn's disease, the pouch failure rates remained higher than in patients with ulcerative colitis.
DISEASES OF THE COLON & RECTUM
(2021)
Review
Gastroenterology & Hepatology
Chiara Rocchi, Youssef Y. Soliman, Marco Massidda, Salvatore F. Vadala di Prampero, Milutin Bulajic, Dario Sorrentino
Summary: Ustekinumab may be a therapeutic option for patients with chronic pouchitis and CD of the pouch refractory to other therapies, but there is limited and inconclusive evidence to support this conclusion.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Shintaro Akiyama, Emma C. Dyer, David T. Rubin
Summary: This study aimed to review the diagnostic approach, prognosis, and management of IPAA with Crohn's disease-like features. It suggests that a diagnostic approach for pouch conditions resembling a Crohn's disease phenotype should be based on history-taking and endoscopic assessment of the pouch. Important prognostic factors include prior disease history and pathology, location of pouch complications, and timing of complications.
DISEASES OF THE COLON & RECTUM
(2022)
Article
Gastroenterology & Hepatology
Maia Kayal, David Kohler, Michael Plietz, Sergey Khaitov, Patricia Sylla, Alexander Greenstein, Marla C. Dubinsky
Summary: In this retrospective cohort analysis, early pouchitis was significantly associated with subsequent development of Crohn's disease-like pouch inflammation, indicating that early pouchitis may serve as an indicator of enhanced mucosal immune activation in the pouch.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Chen Yueying, Feng Jing, Feng Qi, Shen Jun
Summary: A magnetic resonance enterography-based model was constructed in this study to predict the risk of loss of response to infliximab (IFX) in bio-naive patients with Crohn's disease (CD), providing an effective tool for the early estimation of treatment response before biological intervention.
EUROPEAN RADIOLOGY
(2023)
Editorial Material
Gastroenterology & Hepatology
Delia O'Shea, Joseph A. Picoraro
Summary: This retrospective study highlights the challenges and opportunities of characterizing ileal pouch in children who develop de novo CD after IPAA surgery.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Neeraj Narula, Emily C. L. Wong, Parambir S. Dulai, Neil K. Sengupta, John K. Marshall, Jean-Frederic Colombel, Walter Reinisch
Summary: This post hoc analysis suggests that infliximab and ustekinumab have similar efficacy and speed of onset in biologic-naive patients with CD.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Immunology
Chenglin Ye, Sizhe Zhu, Jingping Yuan
Summary: This study analyzed the gene expression profiles of patients with Crohn's disease (CD) and identified two gene subtypes: immune and metabolic. The immune subtype was associated with leukocyte migration and cytokine interactions, while the metabolic subtype was associated with metabolic pathways. The combination of interleukin 1 beta, interleukin 6, and Toll-like receptor 4 effectively distinguished between these two gene subtypes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Yizhong Wang, Xuefeng Gao, Xinyue Zhang, Fangfei Xiao, Hui Hu, Xiaolu Li, Fang Dong, Mingming Sun, Yongmei Xiao, Ting Ge, Dan Li, Guangjun Yu, Zhanju Liu, Ting Zhang
Summary: The study revealed that pediatric CD patients have gut microbial dysbiosis and altered metabolism after IFX therapy, which is related to treatment outcomes. The effects of IFX treatment may be mediated by enriching bacteria taxa that produce SCFAs and BSH, thereby inhibiting inflammation and restoring bile acid metabolism. Some fecal bacteria and metabolites may serve as predictors of IFX therapy outcomes for pediatric CD patients.
Review
Gastroenterology & Hepatology
Sameh Hany Emile, Nir Horesh, Michael R. Freund, Zoe Garoufalia, Rachel Gefen, Sualeh Muslim Khan, Emanuela Silva-Alvarenga, Steven D. Wexner
Summary: Probiotics are effective in preventing pouchitis after IPAA, while antibiotics such as ciprofloxacin and metronidazole are likely effective in treating active pouchitis.
JOURNAL OF GASTROINTESTINAL SURGERY
(2023)
Article
Biochemistry & Molecular Biology
Yiyoung Kwon, Eun-Sil Kim, Yoon-Zi Kim, Yon-Ho Choe, Mi-Jin Kim
Summary: This study aims to measure the concentration of cytokines produced during the inflammation process to investigate if there are any differences in response to treatment of pediatric Crohn's disease and to determine if the initial tumor necrosis factor-alpha (TNF-alpha) level affected the trough concentration of infliximab (IFX).
Article
Pharmacology & Pharmacy
Shuyan Li, Yan Ma, Hongling Sun, Zijun Ni, Shurong Hu, Yan Chen, Meijuan Lan
Summary: This study investigated the adherence to Infliximab (IFX) among Chinese Crohn's disease patients and evaluated the association between medication belief and adherence. The results showed that medication concerns may be a predictive factor of adherence, and by enhancing knowledge and relieving concerns, patients' adherence to IFX can be increased.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Padhmanand Sudhakar, Judith Wellens, Bram Verstockt, Marc Ferrante, Joao Sabino, Severine Vermeire
Summary: Inflammatory bowel disease (IBD) is a global disease that affects the gastrointestinal tract and also has an impact on the mental and emotional well-being of patients. Despite medical advancements, only a third of diagnosed patients achieve short to medium-term remission. Therefore, some patients might resort to complementary and alternative approaches to manage their symptoms. This study reviews the efficacy of these approaches and proposes a patient-centric clinical care model and recommendations.
Letter
Gastroenterology & Hepatology
Lucas Wauters, Raul Y. Tito, Matthias Ceulemans, An Outtier, Leen Rymenans, Chloe Verspecht, Joao Sabino, Marc Ferrante, Severine Vermeire, Tim Vanuytsel, Jeroen Raes
Article
Gastroenterology & Hepatology
Lianne Heuthorst, Houda Harbech, Harmanna J. Snijder, Aart Mookhoek, Geert R. D'Haens, Severine Vermeire, Andre D'Hoore, Willem A. Bemelman, Christianne J. Buskens
Summary: A nationwide pathology study found that there has been a shift in the indication for surgery in patients with ulcerative colitis (UC) over the past 3 decades, with a higher proportion of colorectal cancer (CRC) cases.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Edward V. Loftus, Jean-Frederic Colombel, Ken Takeuchi, Xiang Gao, Remo Panaccione, Silvio Danese, Marla Dubinsky, Stefan Schreiber, Dapo Ilo, Tricia Finney-Hayward, Wen Zhou, Charles Phillips, Yuri Sanchez Gonzalez, Lei Shu, Xuan Yao, Qing Zhou, Severine Vermeire
Summary: This study evaluated the efficacy of once-daily upadacitinib 45 mg in improving symptoms of ulcerative colitis. The analysis of pooled data from two phase 3 trials showed that upadacitinib provided rapid relief of UC symptoms from day 1, with significant improvements maintained until day 14. Patients treated with upadacitinib also achieved reductions in inflammatory markers and significant improvements in quality of life.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Pieter Sinonquel, Alessandro Schiliro, Bram Verstockt, Severine Vermeire, Raf Bisschops
Summary: Diagnosis and therapeutic management in ulcerative colitis rely on difficult-to-quantify endoscopic and histological scorings. Artificial intelligence (AI) can overcome issues of variability and estimation of disease activity. This review provides an overview of recent developments in AI for UC, with a focus on endoscopic assessment, histology correlation, and other applications such as surveillance and therapy monitoring.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Editorial Material
Gastroenterology & Hepatology
Severine Vermeire
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Judith Wellens, Eva Vissers, Christophe Matthys, Severine Vermeire, Joao Sabino
Summary: Inflammatory bowel diseases (IBD) are chronic and incurable conditions affecting the gastrointestinal tract. Despite recent advances in medical management, many patients do not achieve remission and healing of the bowel. Personalized nutrition may be a crucial factor in achieving long-lasting changes in dietary behaviors and improving symptoms and inflammation.
PHARMACOGENOMICS & PERSONALIZED MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Bram Verstockt, Sare Verstockt, Jonathan Cremer, Joao Sabino, Marc Ferrante, Severine Vermeire, Padhmanand Sudhakar
Summary: By profiling the transcriptome of circulating monocytes and CD4 T-cells in patients with inflammatory bowel disease (IBD), potential mechanisms driving disease subtypes were inferred. The study revealed significant differences in gene expression profiles of CD4 T-cells between patients with ileal Crohn's disease (CD) and ulcerative colitis (UC), and identified specific signaling pathways and transcription factors associated with UC and CD. Additionally, novel and repurposable drug targets were discovered for both ileal CD and UC, aiding in the development of targeted therapies for IBD subtypes.
BMJ OPEN GASTROENTEROLOGY
(2023)
Review
Gastroenterology & Hepatology
Severine Vermeire, Virginia Solitano, Laurent Peyrin-Biroulet, Herbert Tilg, Silvio Danese, Hartmut Ehrlich, Didier Scherrer, Paul Gineste, Laurence d'Agay, Bruce E. Sands
Summary: Biologic agents and oral small molecules are the main treatments for IBD, but there is a need for new agents with novel mechanisms of action. miRNAs may be potential therapeutic targets for IBD. Obezafimod, a first-in-class oral small molecule, has shown promise in phase II trials for UC patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Stefan Schreiber, Brian G. Feagan, Laurent Peyrin-Biroulet, Severine Vermeire, Margaux Faes, Kristina Harris, Alessandra Oortwijn, Patrick Daniele, Haridarshan Patel, Silvio Danese
Summary: This study assessed the impact of Filgotinib on the health-related quality of life in patients with ulcerative colitis. The results showed that Filgotinib treatment led to improvements in the patients' quality of life in both the short and long term. The achievement of the comprehensive disease control endpoint was associated with clinically important improvements in quality of life and histological remission.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Medicine, General & Internal
William J. Sandborn, Severine Vermeire, Laurent Peyrin-Biroulet, Marla C. Dubinsky, Julian Panes, Andres Yarur, Timothy Ritter, Filip Baert, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J. Rabbat, Michael Chiorean, Douglas C. Wolf, Bruce E. Sands, Geert D'Haens, Silvio Danese, Martina Goetsch, Brian G. Feagan
Summary: Etrasimod, a selective S1P receptor modulator, demonstrated efficacy and safety as an induction and maintenance therapy for patients with moderately to severely active ulcerative colitis. The trials showed a higher proportion of patients achieving clinical remission with Etrasimod compared to placebo at both induction and maintenance periods. This novel treatment option has the potential to address unmet needs in ulcerative colitis patients.
Article
Gastroenterology & Hepatology
Johan Burisch, Mirabella Zhao, Selwyn Odes, Peter De Cruz, Severine Vermeire, Charles N. Bernstein, Gilaad G. Kaplan, Dana Duricova, Dan Greenberg, Hans O. Melberg, Mamoru Watanabe, Hyeong Sik Ahn, Laura Targownik, Valerie E. H. Pittet, Vito Annese, K. T. Park, Konstantinos H. Katsanos, Marte L. Hoivik, Zeljko Krznaric, Maria Chaparro, Edward V. Loftus, Peter L. Lakatos, Javier P. Gisbert, Willem Bemelman, Bjorn Moum, Richard B. Gearry, Michael D. Kappelman, Ailsa Hart, Marieke J. Pierik, Jane M. Andrews, Siew C. Ng, Renata D'Inca, Pia Munkholm
Summary: The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase worldwide due to the steady increase in prevalence, the chronic nature of the diseases, expensive treatments, intensive monitoring, and their impact on productivity. This Commission urges evaluation of cost increases against improved disease management and the need for data interoperability and big data approaches to assess effectiveness and cost-effectiveness. International collaborations and novel care models should be sought to enhance education and training for clinicians, patients, and policy makers.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Remo Panaccione, Eric B. Collins, Gil Y. Melmed, Severine Vermeire, Silvio Danese, Peter D. R. Higgins, Christina S. Kwon, Wen Zhou, Dapo Ilo, Dolly Sharma, Yuri Sanchez Gonzalez, Si-Tien Wang
Summary: Indirect evidence suggests that Upadacitinib may be more effective than other advanced therapies in achieving clinical response, clinical remission, and endoscopic response in patients with moderately to severely active ulcerative colitis over a one-year period, with similar safety profiles across different therapies.
CROHNS & COLITIS 360
(2023)
Article
Gastroenterology & Hepatology
Stefan Schreiber, Gerhard Rogler, Mamoru Watanabe, Severine Vermeire, Christian Maaser, Silvio Danese, Margaux Faes, Paul Van Hoek, Jeremy Hsieh, Ulrik Moerch, Yan Zhou, Angela de Haas, Christine Rudolph, Alessandra Oortwijn, Edward V. Loftus Jr
Summary: This study reports integrated safety data of Filgotinib 200mg treatment for patients with moderately to severely active ulcerative colitis. The results indicate that Filgotinib is well tolerated with no unexpected safety signals, regardless of age or previous exposure to biologics.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Matthias Lenfant, Bram Verstockt, Joao Sabino, Severine Vermeire, Marc Ferrante
Summary: The study assessed the ability of the modified Mayo endoscopic score (MMES) to predict long-term clinical outcomes in ulcerative colitis (UC) patients, and found that MMES exhibited a benefit in predicting long-term outcomes, although endoscopic improvement remained the strongest predictor during the follow-up period.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)